Medtronic target raised, added to ‘Tactical Outperform’ list at Evercore ISI

Evercore ISI analyst Vijay Kumar raised the firm’s price target on Medtronic to $102 from $100 and keeps an Outperform rating on the shares, which the analyst is also adding to the firm’s “Tactical Outperform” list ahead of earnings from the MedTech, Life Science Tools and Diagnostics group. Evercore has “a distinct bias towards mega caps and value/GARP as we head into” Q2, the analyst tells investors.